More recent clinical trials with GDNF reported failure to reach the primary end point of improvement in motor scores in GDNF recipients relative to placebo control groups [60,64], leading the field to reconsider its therapeutic potential for treating the motor impairments of PD [188]. This evidence concerns the gene GDNF and Parkinson disease.